Primary CNS Lymphoma (PCNSL): Market View, Current and Future Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This reports provides a data-driven overview of the current and future competitive landscape in Primary CNS Lymphoma Therapeutics._x000D_
_x000D_
• In 2024 and 2029, Urban China is anticipated to have the highest number of diagnosed prevalent cases of PCNSL, representing a large proportion of global cases. _x000D_
• Currently, PCNSL treatment relies mostly on off-label agents, and the Bruton's tyrosine kinase (BTK) inhibitors currently available to treat refractory/relapsed (r/r) PCNSL cases._x000D_
• The PCNSL pipeline holds 43 molecules, with no assets in the pre-registration stage, one asset in Phase III development, and another 23 in Phase II._x000D_
• Over the past decade, 171 clinical trials have been conducted in PCNSL. The year with the most studies initiated was 2021 (26 trials) followed by 2020 (24 trials)._x000D_
• During the past 20 months, six mergers and acquisitions and 11 strategic alliances involving companies developing PCNSL assets were completed globally. _x000D_
• There remains a significant unmet need, which is driving pipeline development of BTK inhibitors and novel cell therapies to improve outcomes.
Scope
GlobalData’s Primary CNS Lymphoma: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. _x000D_
_x000D_
Components of the report include:_x000D_
• Disease Landscape_x000D_
• Disease Overview_x000D_
• Epidemiology Overview_x000D_
• Treatment Overview_x000D_
• Marketed Products Assessment_x000D_
• Breakdown by Mechanism of Action, Route of Administration_x000D_
• Product Profiles with Sales Forecast_x000D_
• Pricing and Reimbursement Assessment_x000D_
• Annual Therapy Cost_x000D_
• Time to Pricing and Time to Reimbursement_x000D_
• Pipeline Assessment_x000D_
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration_x000D_
• Product Profiles with Sales Forecast_x000D_
• Late-to-mid-stage Pipeline Drugs_x000D_
• Phase Transition Success Rate and Likelihood of Approval_x000D_
• Clinical Trials Assessment_x000D_
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status_x000D_
• Enrolment Analytics, Site Analytics, Feasibility Analysis_x000D_
• Deals Landscape_x000D_
• Mergers, Acquisitions, and Strategic Alliances by Region_x000D_
• Overview of Recent Deals_x000D_
• Commercial Assessment_x000D_
• Key Market Players_x000D_
• Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Primary CNS Lymphoma Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Primary CNS Lymphoma Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Primary CNS Lymphoma reports